Group 1 - Impinj (PI) shares have increased by 52.5% in the past four weeks, closing at $117.52, with a mean price target of $149.50 indicating a potential upside of 27.2% [1] - The mean estimate consists of eight short-term price targets with a standard deviation of $55.04, where the lowest estimate is $100 (14.9% decline) and the highest is $251 (113.6% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 102.6% over the past month [11][12] Group 2 - The Zacks Rank for PI is 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While price targets are often viewed as important, they can mislead investors, and analysts may set overly optimistic targets due to business incentives [7][8] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price movement, serving as a starting point for further research [9]

Core Viewpoint - Altimmune, Inc. (ALT) shares have increased by 39.4% in the past four weeks, closing at $5.80, with a mean price target of $22.38 indicating a potential upside of 285.9% [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $5.32, where the lowest estimate of $12 suggests a 106.9% increase, and the highest estimate of $28 indicates a potential surge of 382.8% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about ALT's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 2.3% over the past month, with one estimate increasing and no negative revisions [12] - ALT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13]

Core Viewpoint - AstraZeneca (AZN) shows potential for further upside, with a mean price target of $86.07 indicating a 27.9% increase from its current price of $67.30 [1] Price Targets and Estimates - The mean estimate consists of 10 short-term price targets with a standard deviation of $10.38, indicating variability among analysts [2] - The lowest estimate is $67, suggesting a 0.5% decline, while the highest estimate is $103, indicating a potential increase of 53.1% [2] - A low standard deviation signifies strong agreement among analysts regarding price movement direction [9] Analyst Sentiment and Earnings Estimates - Analysts exhibit growing optimism about AZN's earnings prospects, as indicated by upward revisions in EPS estimates [11] - Over the past 30 days, two estimates have increased, leading to a 0.2% rise in the Zacks Consensus Estimate [12] - AZN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely predict actual stock price movements [7] - Analysts may set overly optimistic targets due to business incentives, which can inflate price expectations [8] - Investors should approach price targets with skepticism and not rely solely on them for investment decisions [10]

Shares of Upbound Group (UPBD) have gained 10.1% over the past four weeks to close the last trading session at $24.17, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $37.88 indicates a potential upside of 56.7%.The average comprises eight short-term price targets ranging from a low of $30 to a high of $50, with a standard deviation of $7.12. While the lowest estimate indicates ...

Howard Hughes Holdings (HHH) closed the last trading session at $67.47, gaining 0.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $90.67 indicates a 34.4% upside potential.The average comprises three short-term price targets ranging from a low of $82 to a high of $105, with a standard deviation of $12.50. While the lowest estimate indicates an increase of 21.5% from the current ...

Financial Performance - Sportsman's Warehouse is expected to report a quarterly loss of 6 cents per share for Q4, compared to a loss of 2 cents per share in the same quarter last year [1] - Projected quarterly revenue is $328.67 million, down from $370.39 million a year earlier [1] Recent Developments - On March 12, Sportsman's Warehouse announced that customers can now purchase suppressors online through a partnership with Silencer Central [2] - The company's shares fell by 1.6%, closing at $0.9941 on Monday [2] Analyst Ratings - Craig-Hallum analyst Ryan Sigdahl maintained a Hold rating and reduced the price target from $4 to $3 [5] - Baird analyst Peter Benedict maintained a Neutral rating and cut the price target from $4 to $2.5 [5]